These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21047536)

  • 1. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system.
    Medina OP; Pillarsetty N; Glekas A; Punzalan B; Longo V; Gönen M; Zanzonico P; Smith-Jones P; Larson SM
    J Control Release; 2011 Feb; 149(3):292-8. PubMed ID: 21047536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.
    Pal A; Glekas A; Doubrovin M; Balatoni J; Namavari M; Beresten T; Maxwell D; Soghomonyan S; Shavrin A; Ageyeva L; Finn R; Larson SM; Bornmann W; Gelovani JG
    Mol Imaging Biol; 2006; 8(5):262-77. PubMed ID: 16897320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA.
    Yeh SH; Lin CF; Kong FL; Wang HE; Hsieh YJ; Gelovani JG; Liu RS
    Biomed Res Int; 2013; 2013():549359. PubMed ID: 23956990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
    Niu G; Li Z; Xie J; Le QT; Chen X
    J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
    Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
    Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.
    Yeh HH; Ogawa K; Balatoni J; Mukhapadhyay U; Pal A; Gonzalez-Lepera C; Shavrin A; Soghomonyan S; Flores L; Young D; Volgin AY; Najjar AM; Krasnykh V; Tong W; Alauddin MM; Gelovani JG
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1603-8. PubMed ID: 21220318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
    Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
    Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors.
    Mitrasinovic PM
    Curr Radiopharm; 2013 Mar; 6(1):48-55. PubMed ID: 23278847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.
    Pantaleo MA; Mishani E; Nanni C; Landuzzi L; Boschi S; Nicoletti G; Dissoki S; Paterini P; Piccaluga PP; Lodi F; Lollini PL; Fanti S; Biasco G
    Mol Imaging Biol; 2010 Dec; 12(6):616-25. PubMed ID: 20379787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Analysis of
    Paiva I; Mattingly S; Wuest M; Leier S; Vakili MR; Weinfeld M; Lavasanifar A; Wuest F
    Mol Pharm; 2020 May; 17(5):1470-1481. PubMed ID: 32233491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation.
    Pisaneschi F; Nguyen QD; Shamsaei E; Glaser M; Robins E; Kaliszczak M; Smith G; Spivey AC; Aboagye EO
    Bioorg Med Chem; 2010 Sep; 18(18):6634-45. PubMed ID: 20797871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and preliminary evaluation of
    Lu X; Wang C; Li X; Gu P; Jia L; Zhang L
    Bioorg Med Chem; 2019 Feb; 27(3):545-551. PubMed ID: 30611635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
    Rai K; Takigawa N; Ito S; Kashihara H; Ichihara E; Yasuda T; Shimizu K; Tanimoto M; Kiura K
    Mol Cancer Ther; 2011 Sep; 10(9):1720-7. PubMed ID: 21712475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN; Kim S; Boerner JL; Viola NT
    Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.
    Pal A; Balatoni JA; Mukhopadhyay U; Ogawa K; Gonzalez-Lepera C; Shavrin A; Volgin A; Tong W; Alauddin MM; Gelovani JG
    Mol Imaging Biol; 2011 Oct; 13(5):853-61. PubMed ID: 20859697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
    Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
    BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
    Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
    Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).
    Shokeen M; Anderson CJ
    Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.
    Su H; Seimbille Y; Ferl GZ; Bodenstein C; Fueger B; Kim KJ; Hsu YT; Dubinett SM; Phelps ME; Czernin J; Weber WA
    Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1089-99. PubMed ID: 18239919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.